Chemomab Therapeutics Ltd ADR (CMMB)

$2.47 -0.02 (-0.80%)
Market Cap 15.57M
Revenue (ttm) 0.00
Net Income (ttm) -13.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 74,100
Avg Vol 169,328
Day's Range N/A - N/A
Shares Out 6.16M
Stochastic %K 34%
Beta 0.50
Analysts Strong Sell
Price Target $26.50

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 77 331 0156
Address:
Building 7, Kiryat Atidim, Tel Aviv, Israel
DLTT4489
DLTT4489 Dec. 4 at 7:54 PM
$CMMB watch this garbage for next 3 weeks. You'll see
0 · Reply
lecorb
lecorb Dec. 4 at 1:31 PM
$CMMB December 4, 2025 4:30 AM Expected earnings - Cambium Networks Corporation Cambium Networks Corporation (CMBM) is expected to report $0 for Q3 2025 (Not confirmed)
1 · Reply
Snptrader
Snptrader Dec. 4 at 12:30 PM
$CMMB https://www.clinicaltrialvanguard.com/news/new-nebokitug-phase-2-results-published-for-sclerosing-cholangitis/
0 · Reply
cayman777
cayman777 Dec. 4 at 10:25 AM
$CMMB -Very specific wording from the latest earnings release.
1 · Reply
DLTT4489
DLTT4489 Dec. 3 at 8:33 PM
$JAGX $CMMB $AIM why you looser care? 🤣🤣🤣
0 · Reply
Zdxss1
Zdxss1 Dec. 3 at 7:38 PM
$JAGX $CMMB $AIM Why is this clown interested in the stock?
1 · Reply
DLTT4489
DLTT4489 Dec. 3 at 7:07 PM
$CMMB 🤣🤣🤣
0 · Reply
Snptrader
Snptrader Dec. 3 at 4:59 PM
$CMMB phase 3 protocol is essentially completed and agreed upon with the FDA (they have basically stated that in the last few press releases) and just a few minor logistics need to be resolved per IR. However this isn’t holding up any discussions with potential partners on the funding of trial. 16M market cap seems very very cheap to me.
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 9:45 PM
$JAGX get ready for another split like $CMMB $AIM
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 9:06 PM
$CMMB very positive news, partnership, phase 3, FDA approval, cash in hand for one year, ....🤣🤣🤣
0 · Reply
Latest News on CMMB
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Dec 2, 2025, 8:00 AM EST - 3 days ago

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 24, 2025, 8:00 AM EST - 11 days ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 8:00 AM EST - 15 days ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:00 AM EDT - 3 months ago

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Jun 11, 2025, 8:00 AM EDT - 6 months ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Jun 3, 2025, 8:00 AM EDT - 6 months ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 7 months ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

May 5, 2025, 8:00 AM EDT - 7 months ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Announces New Medical and Clinical Appointments

Apr 15, 2025, 8:00 AM EDT - 8 months ago

Chemomab Announces New Medical and Clinical Appointments

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Mar 27, 2025, 3:18 PM EDT - 9 months ago

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 27, 2025, 8:30 AM EDT - 9 months ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 6, 2025, 8:00 AM EST - 9 months ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 8:00 AM EST - 9 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 19, 2025, 7:00 AM EST - 10 months ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 19, 2024, 7:00 AM EST - 1 year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 30, 2024, 9:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:38 AM EDT - 1 year ago

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 17, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 8, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

May 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 25, 2024, 7:06 AM EDT - 1 year ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Mar 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 20, 2024, 7:00 AM EST - 1 year ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Feb 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 30, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Jan 3, 2024, 7:00 AM EST - 2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 8:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Nov 6, 2023, 4:15 PM EST - 2 years ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Oct 26, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

DLTT4489
DLTT4489 Dec. 4 at 7:54 PM
$CMMB watch this garbage for next 3 weeks. You'll see
0 · Reply
lecorb
lecorb Dec. 4 at 1:31 PM
$CMMB December 4, 2025 4:30 AM Expected earnings - Cambium Networks Corporation Cambium Networks Corporation (CMBM) is expected to report $0 for Q3 2025 (Not confirmed)
1 · Reply
Snptrader
Snptrader Dec. 4 at 12:30 PM
$CMMB https://www.clinicaltrialvanguard.com/news/new-nebokitug-phase-2-results-published-for-sclerosing-cholangitis/
0 · Reply
cayman777
cayman777 Dec. 4 at 10:25 AM
$CMMB -Very specific wording from the latest earnings release.
1 · Reply
DLTT4489
DLTT4489 Dec. 3 at 8:33 PM
$JAGX $CMMB $AIM why you looser care? 🤣🤣🤣
0 · Reply
Zdxss1
Zdxss1 Dec. 3 at 7:38 PM
$JAGX $CMMB $AIM Why is this clown interested in the stock?
1 · Reply
DLTT4489
DLTT4489 Dec. 3 at 7:07 PM
$CMMB 🤣🤣🤣
0 · Reply
Snptrader
Snptrader Dec. 3 at 4:59 PM
$CMMB phase 3 protocol is essentially completed and agreed upon with the FDA (they have basically stated that in the last few press releases) and just a few minor logistics need to be resolved per IR. However this isn’t holding up any discussions with potential partners on the funding of trial. 16M market cap seems very very cheap to me.
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 9:45 PM
$JAGX get ready for another split like $CMMB $AIM
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 9:06 PM
$CMMB very positive news, partnership, phase 3, FDA approval, cash in hand for one year, ....🤣🤣🤣
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 9:05 PM
$CMMB you never learn
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 5:05 PM
$CMMB this scam company will fail sooner than you think
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 5:02 PM
$CMMB 🤣🤣🤣🤣
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 3:15 PM
$CMMB how idiot you can be, unbelievable 👺👺. Pump it again clown 🤡 🤣
0 · Reply
cayman777
cayman777 Dec. 2 at 2:33 PM
$CMMB -They are going to continue to manipulate this on low volume until fda alignment or partnership/buy out.
0 · Reply
lovelylee
lovelylee Dec. 2 at 1:17 PM
$CMMB $SMX $BYND $AMC $AREB
0 · Reply
lovelylee
lovelylee Dec. 2 at 1:14 PM
$CMMB let’s run it up today 💰
0 · Reply
Snptrader
Snptrader Dec. 2 at 1:14 PM
$CMMB 6.1M outstanding $16.5M market cap for a $1.2B disease modifying drug for PSC (with no current effective therapy) entering into a single phase 3 registration trial. Current cash runway through 2026 q4.
1 · Reply
cayman777
cayman777 Dec. 2 at 1:13 PM
$CMMB -American Journal of Gastronenterology. A peer reviewed publication.
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 2 at 1:00 PM
$CMMB Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology https://investors.chemomab.com/2025-12-02-Chemomab-Therapeutics-Announces-Nebokitug-Phase-2-SPRING-Trial-Results-in-Primary-Sclerosing-Cholangitis-Published-in-the-American-Journal-of-Gastroenterology
0 · Reply
Stockhunter008
Stockhunter008 Dec. 2 at 6:34 AM
$CMMB Dec 11thh FDA BTD announcement?
0 · Reply
dom3
dom3 Dec. 1 at 10:49 PM
$CMMB Most small caps down 3 to 5 per cent today. CMMB held well. Lets see if we are three days lucky tuesday. Incredible how cheap it is relative to both its sector and substantial development. The market wants to hear a partnership before we see the big pop.
1 · Reply